Effects of evolocumab on plasma levels of proprotein convertase subtilisin/kexin type 9 and lipoprotein(a) in acute myocardial infarction

28 August 2020 (08:00 - 18:00)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Akihiro Nakamura

Iwate Prefectural Central Hospital, Morioka (Japan)

56 More presentations in this session

Presentation thumbnail

Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects

Professor Y. Huo (Beijing, CN)

Abstract Slides

Presentation thumbnail

Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects

Doctor C. Becker (Wuppertal, DE)

Abstract Slides

Presentation thumbnail

Physiologically-based pharmacokinetic (PBPK) exploration of extrinsic factors influencing vericiguat pharmacokinetics

Doctor S. Frechen (Leverkusen, DE)

Abstract Slides

Presentation thumbnail

Long-term safety and efficacy of bempedoic acid in patients at high risk of atherosclerotic cardiovascular disease: results from the CLEAR Harmony open-label extension study

Doctor C. Ballantyne (Houston, US)

Abstract Slides

Presentation thumbnail

The effect of elevated triglycerides and purified eicosapentaenoic acid ethyl ester (EPA) for cardiovascular risk reduction in the UK Biobank population

Doctor D. Radenkovic (Greater London, GB)

Abstract Slides

Access the full session

Session thumbnail

Pharmacology and Pharmacotherapy ePosters

The Event

ESC Congress 2020

28 August 2020 08:00 CET

You may be interested in

Webinar

Unmet needs in lipid management: treatment goals and how to achieve them

Webinar

New trial evidence in the field of lipid management

Congress Presentation

2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources